On Thursday, in the course of Afternoon trade, Shares of The Medicines Company (NASDAQ:MDCO), dropped -1.63%, and is now trading at $31.51.
The Medicines Company, declared its financial results for the second quarter and first half of 2015.
Second-Quarter 2015 Financial Summary
Worldwide net revenue was $90.5 million for the second quarter of 2015 contrast to $183.8 million in the second quarter of 2014. Worldwide Angiomax/Angiox (bivalirudin) revenue was $65.6 million in the second quarter of 2015 contrast to $163.1 million in the second quarter of 2014, with revenue in the United States decreasing to $60.5 million in the second quarter of 2015 from $152.2 million in the second quarter of 2014. Recothrom, Thrombin topical (Recombinant) sales were $15.9 million contrast to $16.3 million in the second quarter of 2014. Other products counting Cleviprex (clevidipine), Argatroban for Injection, 50 mg per mL, Minocin (minocycline) for injection, Orbactiv (oritavancin) and PreveLeakTM Surgical Sealant recorded sales of $9.0 million during second quarter of 2015 contrast to $4.4 million in the second quarter of 2014. Not taking into account Angiomax, the company recorded 20% higher net revenue during the second quarter of 2015 contrast to the second quarter of 2014.
The net loss for the second quarter of 2015 was $46.6 million, or ($0.71) per share, contrast to a net loss of $5.2 million, or ($0.08) per share, for the second quarter of 2014. Adjusted net loss for the second quarter of 2015 was $42.8 million, or ($0.65) per share, contrast to adjusted net income of $20.6 million, or $0.31per share for the second quarter of 2014.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
Reynolds American Inc., through its auxiliaries, manufactures and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, American Snuff, and Santa Fe segments.
During an Afternoon trade, Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA), dipped -1.57%, and is now trading at $2.51.
Idera Pharmaceuticals, stated its financial and operational results for the second quarter ended June 30, 2015.
“From a program execution perspective, we’ve continued to make steady progress across the board during the second quarter of 2015,” stated Vincent Milano, Idera’s Chief Executive Officer. “We recently declared our planned clinical research alliance with MD Anderson, with the first planned study of this alliance evaluating the combination of IMO-2125 (TLR9 agonist) and ipilimumab (an anti-CTLA4 antibody) in melanoma patients. We are targeting commencing this study in the fourth quarter of this year. Our B-cell lymphoma programs with IMO-8400 (TLR7, 8 and 9 antagonist) are advancing, as we are rapidly approaching the release of data from the Waldenstrom’s macroglobulinemia (WM) trial in the fourth quarter. Also in the second quarter, we began enrolling patients into the first dose cohort in the diffuse large B-cell lymphoma (DLBCL) clinical trial. Our rare disease programs are moving forward nicely, most notably with the initiation of our dermatomyositis Phase 2 study planned for the fourth quarter. Finally, we continue to expect to declare the first two diseases we plan to target with our exciting third generation antisense platform technology, which was formerly referred to as our GSO program, by the end of this year.”
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States.
Shares of Cloud Peak Energy Inc. (NYSE:CLD), during its Thursday’s current trading session climbed 5.79%, and is now trading at $3.29.
SSA Marine, the Crow Tribe of Indians and Cloud Peak Energy, declared that the Crow Tribe and Cloud Peak Energy are joining SSA Marine as partners in the Gateway Pacific Terminal, located in the Northwest corner of Washington state.
The Gateway Pacific Terminal (GPT) is a planned 54 million metric ton, dry bulk, deep water export terminal designed to handle commodities such as coal, grain, and potash. GPT will be the only U.S. Pacific Northwest terminal with natural deep water accommodating cost saving cape size bulk vessels. GPT is presently two and a half years into an unprecedentedly broad and thorough permitting process.
Under this new ownership structure, SSA Marine remains the majority owner retaining 51% of the company’s shares; Cloud Peak Energy owns 49%; and the Crow Tribe will have an option to secure 5% from Cloud Peak Energy.
Cloud Peak Energy Inc., through its auxiliaries, produces coal in the Powder River Basin (PRB) and the United States. The company operates through Owned and Operated Mines, Logistics and Related Activities, and Corporate and Other segments.
Finally, Avis Budget Group Inc. (NASDAQ:CAR), lost -2.18% Thursday.
Avis Car Rental, declared the launch of an updated Android application which enables customers to make, confirm or cancel car rental reservations via voice. The initiative makes Avis the first car rental company to offer this capability.
The improved application guides customers enrolled in Avis Preferred, the Company’s express rental/loyalty program, through the reservation process through spoken and visual prompts for airport rentals around the globe. The application speaks and displays four car classes (compact, intermediate, full-size and luxury) in addition to the car rental’s estimated total cost. Once the reservation is made, customers will automatically receive a confirmation email. In addition, users can use their voice to initiate a call to customer service using the app.
The voice mobility feature builds upon the Company’s commitment to put the customer first by employing the latest technology to enhance the rental experience. To utilize the new feature, travelers must be Avis Preferred members and have their rental preferences on file. With Avis Preferred, members can also earn points for every dollar they spend on vehicle rental and select optional products. In addition, members can skip the counter and paperwork at many locations and go straight to their car, enjoy Avis Preferred Select & Go, the Company’s vehicle selection service accessible at top airport locations in North America, and receive e-receipts upon completion of the vehicle return process, which saves time and paper and eliminates the problem of lost receipts for travel expense accounting.
Avis Budget Group, Inc., together with its auxiliaries, provides car and truck rentals, car sharing, and ancillary services to businesses and consumers worldwide. The company has three segments: North America, International, and Truck Rental.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
